Regenerative Medicine and Stem Cells Technologies

The Director of Neurogen Brain and Spine Institute, India, Dr. Alok Sharma, has described the Stem Cell Therapy as a ray of hope for victims of neurological disorders.

A long-term study of patients who received stem cells to treat angiitis-induced critical limb ischemia (AICLI) shows the cells to be both safe and effective. The study, published in Stem Cells Translational Medicine (SCTM), could lead to an option for those who suffer from this serious form of peripheral arterial disease (PAD

Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury.

CRISPR-Cas13 is an RNA editing technique that can alter protein sequences without modifying the genome in a cell. Recent advances in CRISPR-Cas13 technology mean that it can now be used to locate and even reduce cancer associated gene expression.

In line with transferring technology and technical knowhow, Islamic Republic of Iran intends to set up a number of four equipped research centers in Iraq, Oman, Azerbaijan Republic and Syria.

Scientists from the Hebrew University of Jerusalem have generated an atlas of the human genome using a state-of-the-art gene editing technology and human embryonic stem cells, illuminating the roles that our genes play in health and disease. The scientists have reported their findings in the journal Nature Cell Biology.

Biomedical engineers at Duke University have used a CRISPR/Cas9 genetic engineering technique to turn off a gene that regulates cholesterol levels in adult mice, leading to reduced blood cholesterol levels and gene repression lasting for six months after a single treatment.

Dutch scientists have built "synthetic" embryos in their laboratory using mouse cells other than sperm and eggs.

The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).

A new Japanese joint venture company called MAGiQ Therapeutics — the result of a collaboration between Q Therapeutics and Reprocell — aims to develop cell and gene therapies for demyelinating and degenerative diseases of the central nervous system.